Jul 27, 2021
Starpharma to present DEP® platform at CRS Annual Meeting (ASX Announcement)
Melbourne, Australia; 27 July 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has been invited to present at the prestigious Controlled Release Society (CRS) Virtual Annual Meeting. Starpharma will be represented by its VP of Research, Dr David Owen, who will present an overview of the DEP® platform and its benefits as part of the ‘Success Stories from Bench to Trials to Market’.
The CRS Annual Meeting showcases outstanding research, contributions, and commitment to drug delivery science and technology. It also provides networking opportunities with senior scientific and commercial executives from many major international pharmaceutical companies. This year’s meeting will take place online from 25-29 July 2021 with an estimated 1,300+ global attendees including senior development, licensing and regulatory executives from global pharma and biotech companies, including AstraZeneca, BMS, Roche Pharma, Merck, Novartis, Sanofi, World Health Organisation, US FDA, and Janssen Pharmaceutics (J&J).
Dr Owen’s presentation, “DEP® Drug Delivery - Application for the development of dendrimer-based chemo and radio therapeutics” is scheduled at 10:24am EDT 27 July 2021, and includes:
- Overview of Starpharma’s three Phase 2 clinical-stage assets: DEP® docetaxel, DEP® cabazitaxel, and DEP®
- Performance benefits and broad applicability of DEP® technology including in combination therapies and new technology
- Commercial benefits of Starpharma’s DEP® technology in partnered programs, including AZD0466, which AstraZeneca recently advanced and expanded into a global Phase 1/2 study.
- Snapshot of the Company’s preclinical DEP® pipeline, including DEP® chemotherapeutic, DEP® radiopharmaceutical, and DEP® antibody drug conjugates (ADCs) products.
- Further detail on DEP® ADCs, which have the potential to overcome certain challenges faced by existing ADC approaches.
The presentation can be viewed here.
In addition to Dr Owen’s presentation, Dr Orlagh Feeney of Monash Institute of Pharmaceutical Sciences (MIPS), will present new data on AZD0466 generated under a research collaboration between AstraZeneca, Starpharma, and MIPS. Dr Feeney’s presentation will highlight impressive efficacy data of AZD0466 in a Lymphoma model, demonstrating the potential role of AZD0466 in treating lymphoma.
Starpharma’s DEP® Platform
Starpharma’s dendrimers can be used to enhance the properties of other drugs. The approach is known as “drug delivery” because it is about working to ensure that the drug is delivered to the right part of the body at the right time. Starpharma's dendrimer drug delivery technology is known as DEP®.
Starpharma uses DEP® both in its own drug development pipeline and with partners. The most advanced DEP® products in Starpharma's pipeline are DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, which are in Phase 2 clinical trials.
Benefits of DEP® dendrimer drug delivery include^:
- Improving efficacy
- Reducing toxic side effects of existing drugs
- Extending the duration of activity of the drug in the body
- Targeting drugs to Organs, Tissues, or Molecular Receptors
- Increasing Solubility
- Broad applicability and flexibility with new research areas including radiotheranostics and antibody drug conjugates (ADCs)
Starpharma’s DEP® platform provides exceptional optionality and leverage given that the DEP® technology can be licensed multiple times, and licences are structured to enable multiple partnered DEP® programs to run in parallel. Starpharma now has DEP® programs with multiple large pharma companies, including AstraZeneca, Merck, Chase Sun, and other undisclosed partnerships
^Clinical studies have demonstrated reduction in important side effects with DEP® including bone marrow toxicity, anaphylaxis, oedema, and hair-loss. Multiple preclinical studies have established improved efficacy, survival, and safety with DEP® with many different drugs
Download ASX Announcement: Starpharma to present DEP® platform at CRS Annual Meeting (PDF 520kb)